Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Breathe America (Nashville, TN) a commercial-stage clinical company focused on the treatment of chronic airway diseases, allergy, sinus and asthma, closed a $22M Series B financing. Participants include Essex Woodlands. Thanx for your patience as we catch-up.

Circassia (United Kingdom) a clinical-stage specialty biopharmaceutical company focused on allergy and autoimmune conditions, closed a $98M Series D financing. Participants include Imperial Innovations and Invesco Perpetual.

Anergis (Switzerland) a clinical-stage biopharmaceutical company focused on immunotherapies against allergies, closed announced today that it has closed a $14.3M Series A financing. Participants include Vinci Capital, BioMedInvest, Sunstone Capital, Esperante Ventures and Initiative Capital Romandie.

Circassia (United Kingdom) a clinical-stage specialty biopharmaceutical focused on therapeutic T-cell vaccines for allergies and organ transplant rejection, closed a $25M Series C financing. Participants include Imperial Innovations, Invesco Perpetual and Lansdowne Partners. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jado Technologies (Germany) early-stage developer of small molecule allergy and antiinfective therapeutics, closed a $4.9M Series B financing. Participants include Peppermint Financial Partners, NRW Bank, Dresden Fonds, EMBL Ventures, ERP-Startfonds, Max Planck Society and MASA Life Science Ventures.

ImVision Therapeutics (Germany) biopharmaceutical company focused on intralymphatic immunotherapy for allergies, closed a $4.6M Series A financing. Participants include Aravis Venture Associates AG and Nextech Venture.

RegImmune (Mountain View, CA) early-stage biopharmaceutical company focused on the treatment of graft versus host disease, allergies, autoimmune diseases and other inflammatory diseases, closed a $8M Series B financing. Participants include NIF SMBC Ventures, CSK Venture Capital, Japan Asia Investment Co, and Yasuda Enterprise Development Co.

  

to top of page...